Cargando…

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

OBJECTIVE: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammerness, Paul, McCarthy, Katherine, Mancuso, Elizabeth, Gendron, Cassandra, Geller, Daniel
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695220/
https://www.ncbi.nlm.nih.gov/pubmed/19557116
_version_ 1782168171339317248
author Hammerness, Paul
McCarthy, Katherine
Mancuso, Elizabeth
Gendron, Cassandra
Geller, Daniel
author_facet Hammerness, Paul
McCarthy, Katherine
Mancuso, Elizabeth
Gendron, Cassandra
Geller, Daniel
author_sort Hammerness, Paul
collection PubMed
description OBJECTIVE: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD). METHODS: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD. RESULTS: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported. CONCLUSIONS: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.
format Text
id pubmed-2695220
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26952202009-06-16 Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review Hammerness, Paul McCarthy, Katherine Mancuso, Elizabeth Gendron, Cassandra Geller, Daniel Neuropsychiatr Dis Treat Expert Opinion OBJECTIVE: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD). METHODS: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD. RESULTS: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported. CONCLUSIONS: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity. Dove Medical Press 2009 2009-04-08 /pmc/articles/PMC2695220/ /pubmed/19557116 Text en © 2009 Hammerness et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Expert Opinion
Hammerness, Paul
McCarthy, Katherine
Mancuso, Elizabeth
Gendron, Cassandra
Geller, Daniel
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_full Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_fullStr Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_full_unstemmed Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_short Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
title_sort atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695220/
https://www.ncbi.nlm.nih.gov/pubmed/19557116
work_keys_str_mv AT hammernesspaul atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview
AT mccarthykatherine atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview
AT mancusoelizabeth atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview
AT gendroncassandra atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview
AT gellerdaniel atomoxetineforthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadolescentsareview